Semaglutide is a prescription medication that mimics a natural gut hormone to reduce appetite and slow digestion, leading to significant weight loss. Originally developed for type 2 diabetes, it gained FDA approval for weight management under the brand name Wegovy and has become one of the most widely discussed medications in recent years.
How Semaglutide Causes Weight Loss
Your body naturally produces a hormone called GLP-1 after you eat. This hormone tells your brain you’re full and signals your stomach to digest food more slowly. Semaglutide is a synthetic version of that hormone, engineered to last much longer in your body than the natural version does.
The medication works through two main pathways. First, it slows stomach emptying, so food stays in your stomach longer and you feel full well after a meal. Second, it acts on appetite centers in the brain, increasing feelings of fullness and reducing the drive to eat. The combined effect is that people simply eat less without feeling like they’re fighting hunger all day. Most people notice their interest in food drops noticeably, particularly cravings for high-calorie foods.
Who Can Get a Prescription
The FDA approved Wegovy (the weight-loss formulation of semaglutide) for adults with obesity, defined as a BMI of 30 or higher, or adults with a BMI of 27 or higher who also have at least one weight-related health condition such as high blood pressure, type 2 diabetes, or high cholesterol. It’s also approved for children aged 12 and older with obesity. In all cases, it’s meant to be used alongside a reduced-calorie diet and increased physical activity, not as a standalone fix.
Semaglutide is not appropriate for everyone. It’s contraindicated for anyone with a personal or family history of medullary thyroid carcinoma or a rare genetic condition called Multiple Endocrine Neoplasia syndrome type 2. It also shouldn’t be used by anyone who has had a severe allergic reaction to semaglutide or any of its ingredients.
How It’s Taken
Semaglutide for weight loss is a once-weekly injection you give yourself at home using a prefilled pen. You inject it under the skin of your abdomen, thigh, or upper arm, rotating the site each week. It can be taken on any day, at any time, with or without food, as long as you keep the same day each week.
The dose starts low and increases gradually over about four months to give your body time to adjust and reduce side effects. The schedule looks like this:
- Weeks 1 through 4: 0.25 mg per week
- Weeks 5 through 8: 0.5 mg per week
- Weeks 9 through 12: 1 mg per week
- Weeks 13 through 16: 1.7 mg per week
- Week 17 onward: 2.4 mg per week (maintenance dose)
Some adults stay at 1.7 mg if they can’t tolerate the full 2.4 mg dose. For adolescents aged 12 and older, the target maintenance dose is 2.4 mg. This slow ramp-up is deliberate. Jumping straight to the full dose would cause far more nausea and digestive discomfort.
Common Side Effects
Digestive issues are by far the most frequent side effects. Nausea tops the list, affecting roughly one in five people in clinical trials. Diarrhea, vomiting, constipation, and indigestion also occur regularly. Among the class of medications semaglutide belongs to, it carries a notably higher risk of diarrhea compared to similar drugs.
These side effects tend to be worst during the dose-escalation phase, when your body is adjusting to each new level. For many people, nausea fades or becomes manageable after a few weeks at a stable dose. Eating smaller meals, avoiding fatty or greasy foods, and staying hydrated can help. Reduced appetite, reported by about 5% of trial participants as a distinct side effect, is in many ways the intended therapeutic effect.
The Thyroid Warning
Semaglutide carries the FDA’s most serious label warning, a boxed warning, related to thyroid tumors. In rodent studies, the drug caused thyroid C-cell tumors at doses comparable to what humans take. Whether this translates to humans remains unknown. Out of caution, the FDA requires that patients be counseled about this risk and told to watch for symptoms like a lump in the neck, difficulty swallowing, shortness of breath, or persistent hoarseness.
Heart Health Benefits
Semaglutide’s benefits extend beyond the scale. The landmark SELECT trial found that the drug reduced the risk of major cardiovascular events (heart attack, stroke, and cardiovascular death) by 20% in adults who had both established heart disease and obesity or overweight, but did not have diabetes. This led the FDA to approve Wegovy specifically for reducing cardiovascular risk in that population, making it the first weight management drug to earn such an indication.
What Happens When You Stop
This is the part that catches many people off guard. Semaglutide manages weight the way blood pressure medication manages blood pressure: it works while you take it. A systematic review published in The BMJ estimated that people regain an average of about 10 kg (22 pounds) within the first year after stopping newer medications like semaglutide. At that rate of regain (roughly 0.4 kg per month across weight-loss medications generally), most people are projected to return to their starting weight within about a year and a half of discontinuing treatment.
This doesn’t mean the medication failed. It means the biological drivers of weight, appetite hormones, metabolic adaptation, brain signaling, reassert themselves once the drug is removed. For this reason, many clinicians view semaglutide as a long-term or even lifelong treatment for people with obesity, much like statins for cholesterol. The decision to continue or stop involves weighing cost, side effects, and individual health goals with your prescriber.